FDA Fast-Tracks PleoPharma's Investigational New Drug for Mitigation

mg Magazine – Cannabis News & Information

Factuality

Ownership

FDA Fast-Tracks PleoPharma's Investigational New Drug for Mitigation

PHOENIXVILLE, Pa. — The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, PleoPharma Inc.’s investigational new drug (IND) application for the mitigation of cannabis withdrawal syndrome. “We are pleased that PP-01 has been granted Fast Track designation and are grateful to the FDA for recognizing the significance of cannabis withdrawal for the growing population with cannabis use disorder,” said CEO Ginger Cons…